Biotechnology and Bioeconomy
Industrial biology, bio-based materials, enzymes, fermentation and circular biological production in European strategic autonomy
23 pages · PDF · 04 July 2026 · Licensed single-user copy, watermarked to the buyer
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Europe’s bioeconomy is moving from environmental policy into the harder terrain of industrial capability.
The strategic issue is no longer whether biotechnology can produce cleaner materials, ingredients or chemicals, but whether Europe can turn enzymes, fermentation, biorefineries, biomaterials and circular biological production into scalable assets that reduce dependence on imported fossil-based inputs, petrochemical intermediates, agricultural inputs and non-European production platforms. This is why the relevant biotechnology universe is not the ordinary healthcare equity market.
Key questions this report answers
- Can Europe convert enzymes, fermentation, biorefineries and biomaterials into scalable industrial assets that reduce dependence on imported fossil-based inputs?
- When does industrial biology create value by scaling through unit operations rather than at the discovery stage?
- How does Europe's evolving policy architecture treat biotechnology as an industrial-scale capability?
- What is the DFM assessment of Europe's strategic biotechnology base and its principal gaps?
Inside this report
- Strategic autonomy begins with inputs, process know-how and domestic production
- Industrial biology is valuable when it scales through unit operations, not when
- Europe’s policy architecture now recognises biotechnology as an industrial scale
- The DFM assessment is that Europe has a credible strategic biotechnology base, b
Who it's for
Strategy, corporate-development and investment teams that need an ecosystem-level view — budgets, industrial capacity and technology landscapes — before committing capital or capacity.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (04 July 2026). You receive a 23-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Strategic reports · Synthetic Biology · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →